Preliminary Evaluation Of ION-ZC1 As A Potential Anticancer Agent In Vitro
Completed in 2018 by Brooklyn College and The City University of New York, USA.
The ION-ZC1 solution is a responsive cytotoxic agent against:
Renal carcinoma cell line Caki-1 (IC50 36.12 ± 1.00 μM),
Triple-Negative Breast Cancer (MDA-MB-231),
and Melanoma cancer cell line A375 (IC50 95.20 ± 1.01 μM)
Highly selective when compared to the cytotoxicity of ION-ZC1 on control cells IMR-90 (IC50 142.6 ± 6.65 μM).
The ION-ZC1 solution induces apoptotic death in 92% of renal carcinoma cell line Caki-1 at dose IC50 36.12 ± 1.00 μM.
ION-ZC1 Topical Cream Anti-Tumor Efficacy Study Using A Syngeneic Mouse Melanoma Model (B16F0 – C57BL/6J), Study Design Of 30 Mice.
Completed in 2017 by the University of Debrecen, Hungary.
The main conclusion drawn from the study is that ION-ZC1 Topical Cream (17%) is:
Significantly efficacious against metastatic mouse melanoma as tested in a subcutaneous syngeneic mouse model (B16-F0 in C57BL/6J mice).
More efficacious than the Imiquimod Topical Cream (5%).
Tumor volumes recorded over the treatment period in the three groups support that tumor growth was slower as inhibited by ION-ZC1 Topical Cream (17%), and its effect was more pronounced as compared to the inhibitory effect of ALDARA (5% Imiquimod) Positive Control substance on tumor growth.
ION-ZC1 Anti-Tumor Efficacy Study By Intravenous Injection (Parenteral) Route, Using A Syngeneic Mouse Xenograft Model, More Specifically A Subcutaneous B16 Mouse Melanoma Model In C57BL/6J, Study Design Of 30 Mice.
Completed in 2016 by the University of Debrecen, Hungary.
Safety abnormalities compared to control tumor mice were not noted for any of the animals when necropsied at the conclusion of the 14-day observation period. As the most important results from the histopathological analysis, we can state that:
Tumors isolated from mice treated with various concentrations of ION-ZC1 IV injections show massive necrosis, which is not pronounced as much in tumors isolated from control tumor mice;
Blood vessels are much less frequent, less developed in the ION-ZC1 treated mice compared to control tumor mice.
ION-ZC1 injection results in spleen enlargement, which is remarkably (2-3 times) bigger in extent than that of the spleen of control (untreated) tumor mice, and consistent with ION-ZC1 inducing a strong anti-tumor immune response.
